Sequential Use of Nitazoxanide (NTZ) as a Salvage Therapy in Patient with Recurrent Mild to Moderate Clostridium Difficile Infection (CDI): A Prospective, Open-label, Randomized Clinical Trial: 386

@article{Basu2010SequentialUO,
  title={Sequential Use of Nitazoxanide (NTZ) as a Salvage Therapy in Patient with Recurrent Mild to Moderate Clostridium Difficile Infection (CDI): A Prospective, Open-label, Randomized Clinical Trial: 386},
  author={P. Basu and N. Shah and N. Krishnaswamy and R. Korapati and Chris Tang and Tommy Pacana},
  journal={The American Journal of Gastroenterology},
  year={2010},
  volume={105}
}
Treatment of recurrent Clostridium difficile infection: a systematic review
TLDR
Heterogeneity in treatment duration and dose precludes robust conclusions but metronidazole and vancomycin have good evidence for use in RCDI, and fidaxomicin may have a role in treatment, but evidence is limited to subgroup analyses. Expand